Drug Profile
Research programme: small molecule therapeutics - Adlai Nortye
Alternative Names: AN 1015; AN 2015; AN 3005; IDO inhibitor - Adlai Nortye; Indoleamine-pyrrole- 2,3-dioxygenase inhibitor - Adlai NortyeLatest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Adlai Nortye
- Class Antineoplastics; Small molecules
- Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Breast cancer; Cancer; Mantle-cell lymphoma; Myelodysplastic syndromes; Non-small cell lung cancer
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for research development in Acute-myeloid-leukaemia in China
- 28 Dec 2021 No recent reports of development identified for research development in Breast-cancer in China
- 28 Dec 2021 No recent reports of development identified for research development in Mantle-cell-lymphoma in China